AI Analysis AI Analysis of BCDA AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add BCDA to Watchlist?
Some Reasons Why To Add BCDA:
  • Lower volatility than the market (beta 0.50)
  • Highly efficient cash conversion (100% FCF/OCF ratio)
  • Established player in the Healthcare sector
PDF

BioCardia, Inc. stock downgraded to Hold/Accumulate
(Updated on Jul 02, 2026)

Buy or Hold candidate since Jun 22, 2026 Gain 24.12%

The BioCardia, Inc. stock price gained 0.84% on the last trading day (Thursday, 2nd Jul 2026), rising from $1.19 to $1.20. During the last trading day the stock fluctuated 4.70% from a day low at $1.17 to a day high of $1.23. The price has risen in 8 of the last 10 days and is up by 26.64% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 110 thousand more shares were traded than the day before. In total, 361 thousand shares were bought and sold for approximately $433.55 thousand.

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $1.23 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -15.61% during the next 3 months and, with a 90% probability hold a price between $0.627 and $1.04 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

BCDA Signals & Forecast

The BioCardia, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $1.17 and $0.98. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). BioCardia, Inc. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, June 30, 2026, and so far it has fallen -3.23%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for BioCardia, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $1.11 and $1.03. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, BioCardia, Inc. finds support just below today's level at $1.11. If this is broken, then the next support from accumulated volume will be at $1.03 and $0.92.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.0550 between high and low, or 4.70%. For the last week, the stock has had daily average volatility of 9.31%.

The BioCardia, Inc. stock is overbought on RSI14 and lies in the upper part of the trend. Normally this may pose a good selling opportunity for the short-term trader, but some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.

Our recommended stop-loss: $1.15 (-4.48%) (This stock has very high daily movements and this gives very high risk. The RSI14 is 84 and this increases the risk substantially. There is a sell signal from a pivot top found 2 days ago.)

Trading Expectations (BCDA) For The Upcoming Trading Day Of Monday 6th

For the upcoming trading day on Monday, 6th we expect BioCardia, Inc. to open at $1.20, and during the day (based on 14 day Average True Range), to move between $1.15 and $1.25, which gives a possible trading interval of +/-$0.107 (+/-9.37%) up or down from last closing price. If BioCardia, Inc. takes out the full calculated possible swing range there will be an estimated 9.37% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $1.21 (0.83%) than the support at $1.11 (7.50%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is BioCardia, Inc. stock A Buy?

BioCardia, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold candidate.

Current score: 0.327 Hold/Accumulate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on July 6, 2026 - $1.20 ( 0.139%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

BCDA Performance

Trading levels for BCDA

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 1.25 4.44%
R2 1.23 2.69%
R1 1.22 1.61%
Price 1.20
S1 1.18 -1.89%
S2 1.16 -2.97%
S3 1.14 -4.72%

Accumulated Volume Support & Resistance Levels

Level Price
R3 1.25 4.17%
R2 1.24 3.33%
R1 1.21 0.83%
Price 1.20
S1 1.11 -7.50%
S2 1.03 -14.17%
S3 0.92 -23.33%

FAQ

What is the symbol for BioCardia, Inc. Stock and on which exchange is it traded?
The symbol for BioCardia, Inc. is BCDA and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell BioCardia, Inc. Stock?
BioCardia, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold candidate.

How to buy BioCardia, Inc. Stock?
BioCardia, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy BioCardia, Inc. Stock.

What's the current price of BioCardia, Inc. Stock?
As of the end of day on the Jul 02, 2026, the price of an BioCardia, Inc. (BCDA) share was $1.20.

What is the 52-week high and low for BioCardia, Inc. Stock?
The 52-week high for BioCardia, Inc. Stock is $2.44 and the 52-week low is $0.777.

What is the market capitalization of BioCardia, Inc. Stock?
As of the Jul 02, 2026, the market capitalization of BioCardia, Inc. is 6.959M.

When is the next earnings date for BioCardia, Inc.?
The upcoming earnings date for BioCardia, Inc. is Aug 10, 2026.
Click to get the best stock tips daily for free!
ABOUT BIOCARDIA, INC.
BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture...
GOLDEN STAR
Ticker Change Signal Date
B
BXDC
$21.71
1.11% Jun 29
SRPT
$17.02
13.28% Jun 29
OSIS
$218.29
1.59% Jun 26
NMRK
$15.02
4.66% Jun 24
JLL
$299.78
9.23% Jun 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE